SAN RAMON, Calif., May 4, 2011 /PRNewswire/ -- Odyssey Thera, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 7,935,493, entitled "Protein fragment complementation assays for high-throughput and high-content screening."
Claims granted in the patent broadly cover the application of contextual high-content assays to diverse biological events, and the use of these methods for novel drug discovery and drug re-indication. The concept of utilizing drugs with well-established pharmacology and safety characteristics for a novel therapeutic focus – drug re-indication or "re-repurposing" – has been proposed as a solution for improving success rates of therapeutic development(1).
"This patent, in concert with our existing IP, provides unprecedented coverage of cellular signaling space," said John K. Westwick, Ph.D., Odyssey Thera President and CEO. "Access to all target classes and pathways is essential for deciphering compound and target mechanisms. Technologies protected by this patent, combined with our proprietary strategies for expediting preclinical development, represent a unique platform for fast-tracking new therapeutic development."
About Odyssey Thera
Odyssey Thera, Inc. is a privately held technology company committed to developing breakthroughs in cellular and biochemical analysis. Novel technologies developed at Odyssey are improving the success rate of new therapeutic development, and providing new solutions for environmental monitoring, diagnostic, bioprocess and agricultural applications. To learn more about Odyssey Thera, please visit www.odysseythera.com.
(1) Huang, R. et al., (2011) Science Translational Medicine; Apr 27;3(80):80ps16.
SOURCE Odyssey Thera, Inc.